Correction

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer (vol 21, 135, 2019)

Journal

BREAST CANCER RESEARCH
Volume 22, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13058-020-1254-5

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available